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Abstract: 
 
Four new homoisoflavonoids, 7-O-methyl-8-demethoxy-3′-hydroxy-3,9-dihydropunctatin (4), 6-
hydroxy-8-demethoxy-4′-O-methyl-3,9-dihydropunctatin (8), 7,4′-O-dimethyl-8-demethoxy-3,3′-
dihydroxy-3,9-dihydropunctatin (13), and 7-O-methyl-3-hyroxy-3,9-dihydropunctatin (14) were 
identified from a chloroform extract of the bulbs of Bellevalia flexuosa, along with 13 known 
analogues. The structures were determined by analysis of HRMS and NMR data, while ECD 
spectroscopy enabled the assignment of the absolute configurations of the new compounds 4, 8, 
13 and 16. The cytotoxic activities of the isolated compounds (1–17) were evaluated using a 
panel of human cancer cell lines. Compounds 2 and 7 were the most potent against the MDA-
MB-435 (melanoma) cancer cell line with IC50 values of 1.6 and 2.0 μM, respectively, and were 
essentially equipotent against the OVCAR3 (ovarian) cancer cell line with IC50 values of 9.5 and 
10.8 μM, respectively. However, compound 7, with an IC50 value of 3.6 μM, was the most potent 
against the MDA-MB-231 (breast) cancer cell line. 
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Article: 
 
1. Introduction 
 
Homoisoflavonoids are a rare subclass of flavonoids possessing an extra carbon atom in their 
skeleton [1, 2, 3, 4, 5]. Biosynthetically, chalcones are thought to be the precursors of 
homoisoflavonoids [3]. Currently, about 250 natural homoisoflavonoids have been reported in 
the literature, with the majority being isolated from several genera of Asparagaceae and 
Fabaceae [1, 2, 3, 4, 6, 7]. Based on their structures, homoisoflavonoids have been classified into 
five groups: 3-benzyl-4-chromanones, 3-benzyl-3-hydroxy-4-chromanones, 3-benzylidene-4-
chromanones (E or Z), 3-benzylchrom-2-en-4-ones, and the scillascillins [4]. Homoisoflavonoids 
have attracted attention because of their various biological activities, including antioxidant, anti-
inflammatory, antimutagenic, antimicrobial, antiallergic and antihistaminic, anti-diabetic, 
cytotoxic, and anti-angiogenic effects, as well as protein tyrosine kinase inhibition activity [3,4]. 
 
Although Jordan is a small country of about 96,188 km2, it has a remarkable diversity of wildlife, 
which could be attributed to its unique location at the intersection of three continents, 
encapsulating four bio-geographical zones: Mediterranean, Irano-Turanian, Saharo-Arabian, and 
Tropical (Sudanian penetration) [8, 9, 10]. Within these different zones, thirteen vegetation types 
are identified, reflecting Jordan's diverse landscape, climate, and geology [8,11]. >2600 vascular 
plant species belonging to 113 family and 810 genera are reported to grow in the wild, of which 
100 are endemic and >70 species are considered extinct [8]. Hence, studies of Jordan's wild 
plants have been initiated [12, 13, 14] as a potential source of drug leads. 
 
In the current study, the bulbs of Bellevalia flexuosa Boiss. (Asparagaceae) have been explored. 
B. flexuosa, which is known as “Common Roman Squill”, and in Jordan as “Drooping Onion” 
[15], is one of eleven species that are reported by Al-Eisawi to grow in Jordan in the wild [16]. 
Although no medical use is reported for this plant species by the local people of Jordan, a closely 
related species (B. eigii) was investigated recently, yielding a set of homoisoflavoinids [6]. B. 
flexuosa is a perennial herb with underground bulbs that is found flowering from February to 
March. It flourishes in mountains and waste grounds [16]. Chemical investigation of the 
chloroform extract of the bulbs of B. flexuosaresulted in the isolation and identification of 
seventeen homoisoflavonoids; of which thirteen were known (1–3, 5–7, 9–12, and 15–17) and 
four were new analogues: 7-O-methyl-8-demethoxy-3′-hydroxy-3,9-dihydropunctatin (4), 6-
hydroxy-8-demethoxy-4′-O-methyl-3,9-dihydropunctatin (8), 7,4′-O-dimethyl-8-demethoxy-3,3′-
dihydroxy-3,9-dihydropunctatin (13), and 7-O-methyl-3-hyroxy-3,9-dihydropunctatin (14). ECD 
spectroscopy was used to assign the absolute configurations of the new compounds 4, 8, 13, and 
14. Homoisoflavonoids were reported to have a broad range of biological activities, including 
cytotoxic effects [3]. Therefore, the isolated compounds (1–17) were tested for their cytotoxicity 
using three human cancer cell lines, namely MDA-MB-435 (melanoma), MDA-MB-231 
(breast), and OVCAR3 (ovarian). 
 
2. Experimental 
 
2.1. General experimental procedures 
 
Optical rotations, UV data, and ECD spectra were obtained using a Rudolph Research Autopol 
III polarimeter (Rudolph Research Analytical), a Varian Cary 100 Bio UV–vis 
spectrophotometer (Varian Inc.), and an Olis DSM 17 ECD spectrophotometer (Olis, Inc.). NMR 
data were collected using either a JEOL ECA-500 NMR spectrometer operating at 500 MHz 
for 1H and 125 MHz for 13C (JEOL Ltd.) or an Agilent 700 MHz NMR spectrometer (Agilent 
Technologies), equipped with a cryoprobe, operating at 700 MHz for 1H and 175 MHz for 13C. 
Residual solvent signals were utilized for referencing. HRMS data were acquired using a Thermo 
QExactive Plus mass spectrometer equipped with an electrospray ionization source (Thermo 
Fisher Scientific). Gemini–NX C18 analytical (5 μm; 250 × 4.6 mm) and preparative (5 μm; 
250 × 21.2 mm) columns (both from Phenomenex) along with Atlantis T3 C18 analytical (5 μm; 
250 × 4.6 mm) and semipreparative (5 μm; 250 × 10.0 mm) columns (both from Waters Corp.) 
were used on a Varian Prostar HPLC system equipped with ProStar 210 pumps and a Prostar 335 
photodiode array detector (PDA), with data collected and analyzed using Galaxie 
Chromatography Workstation software (version 1.9.3.2, Varian Inc.). Flash chromatography was 
performed on a Teledyne ISCO CombiFlash Rf 200 using Silica Gold columns (both from 
Teledyne Isco) and monitored by UV and evaporative light-scattering detectors. All other 
reagents and solvents were obtained from Fisher Scientific and were used without further 
purification. 
 
2.2. Plant material 
 
Bulbs of B. flexuosa were collected by Mohammad Bashabshah during flowering stage from the 
campus of the Jordan University of Science and Technology (JUST), Irbid, Jordan in 
March/April 2016. The plant material was identified by Mohammad Al-Gharaibeh, Plant 
Taxonomist, Faculty of Agriculture, JUST. A voucher specimen (PHS-122) was deposited in the 
herbarium of the Faculty of Pharmacy, JUST. The bulbs were cleaned of mud, sliced into small 
pieces, and air dried at rt. in a well-ventilated area. 
 
2.3. Extraction and isolation 
 
Air-dried bulbs of B. flexuosa were ground to a powder using a laboratory mill. The powdered 
bulbs (850 g) were extracted exhaustively with CHCl3 by soaking at rt. The solvent was 
evaporated under reduced pressure to yield the CHCl3 extract (3.1 g), which was reconstituted in 
a 500 mL mixture of 5:4:1 H2O:CHCl3:MeOH. The mixture was stirred for 30 min and left to 
separate in a separatory funnel. The organic layer was collected and evaporated to dryness under 
reduced pressure. The dried organic extract was reconstituted in 200 mL of 1:1 MeOH:CH3CN 
and 200 mL of hexanes and transferred into a separatory funnel. The biphasic solution was 
shaken vigorously. The MeOH/MeCN layer was evaporated to dryness under vacuum. The dried 
MeOH/CH3CN layer (2.1 g) was dissolved in CHCl3 and mixed with Celite 545. Normal-phase 
flash chromatography was run using a gradient solvent system of hexanes-CHCl3-MeOH, at a 
flow rate of 35 mL/min, and column volumes of 41.3 over a total run time of 30.7 min, to yield 
seven fractions. Fraction 3 (267.9 mg) was subjected to preparative HPLC over a Gemini column 
using a gradient system of 50:50 to 60:40 of MeOH-H2O (0.1% formic acid) over 30 min at a 
flow rate of 20 mL/min to yield 8 subfractions, of which subfraction 3 was identified as 
compound 15 (2.1 mg). Subfraction 7 (1.9 mg) was subjected to semipreparative HPLC 
purification over Atlantis T3 column using a gradient solvent system of 40:60 to 50:50 CH3CN-
H2O (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min to yield compounds 5 (0.7 mg) 
and 13(0.4 mg). Subfraction 8 (8.3 mg) was subjected to semipreparative HPLC using Atlantis 
T3 column and a gradient solvent system of 40:60 to 60:40 CH3CN-H2O (0.1% formic acid) over 
20 min at a flow rate of 4.6 mL/min to yield compounds 7 (5.4 mg) and 13 (0.3 mg). 
 
Fraction 4 (544.7 mg) was subjected to preparative HPLC over a Gemini column using a gradient 
system of 60:40 to 70:30 of MeOH-H2O (0.1% formic acid) over 20 min at a flow rate of 
21.2 mL/min to yield compound 5 (335.6 mg). 
 
Fraction 5 (116.0 mg) was subjected to preparative HPLC over a Gemini column using a gradient 
system of 50:50 to 70:30 of MeOH-H2O (0.1% formic acid) over 20 min at a flow rate of 
21.2 mL/min to yield seven sub-fractions. Further HPLC purification of subfractions 3 (3.4 mg) 
and 4 (3.2 mg) using semipreparative HPLC (Atlantis T3 column) and a gradient solvent systems 
of 40:60 to 50:50 CH3CN-H2O (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min 
yielded compounds 17 (1.3 mg) and 2 (2.1 mg) from subfractions 3 and 4, respectively. 
Subfractions 6 (2.2 mg) and 7 (14.3 mg) were purified using semipreparative HPLC (Atlantis T3 
column) and a gradient solvent system of 40:60 to 60:40 CH3CN-H2O (0.1% formic acid) over 
20 min at a flow rate of 4.6 mL/min to yield compounds 4 (0.9 mg) and 16 (10.8 mg) from 
subfractions 6 and 7, respectively. 
 
Fraction 6 (379.3 mg) was purified using preparative HPLC (Gemini column) and a gradient 
solvent system of 50:50 to 55:45 of MeOH-H2O (0.1% formic acid) over 20 min, hold for 5 min 
and then increasing to 60:40 over 10 min at a flow rate of 21.2 mL/min to yield 5 subtractions. 
Subfraction 1 (13.2 mg) was further purified using semipreparative (Atlantis T3 column) and a 
gradient solvent system of 30:70 to 40:60 CH3CN-H2O (0.1% formic acid) over 15 min at a flow 
rate of 4.6 mL/min to yield compound 8 (2.3 mg) and another subfraction that was further 
purified using semipreaprative HPLC method over Atlantis T3 column and an isocratic solvent 
system of 28:72 CH3CN-H2O (0.1% formic acid) for 50 min at a flow rate of 4.6 mL/min to yield 
compounds 9 (2.3 mg) and 14 (1.9 mg). Subfractions 2 (15.6 mg) and 3 (39.0 mg) were purified 
using semipreparative HPLC (Atlantis T3 column) and a gradient solvent systems of 40:60 to 
60:50 CH3CN-H2O (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min to yield 
compound 6 (9.1 mg) from subfraction 2 and compounds 3 (1.4 mg), 6 (1.9 mg), and 10 
(19.2 mg) from subfraction 3. Subfractions 4 (3.4 mg) and 5 (3.8 mg) were purified using 
semipreparative HPLC (Atlantis T3 column) and gradient solvent systems of 40:60 to 50:50 
CH3CN-H2O (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min to yield compounds 1 
(0.5 mg) and 10 (0.5 mg) from fraction 4 and compounds 2 (0.9 mg), 5 (2.3 mg), 11 (0.9 mg), and 
12 (1.5 mg) from subfraction 5. 
 
2.3.1. 7-O-Methyl-8-demethoxy-3′-hydroxy-3,9-dihydropunctatin (4) 
 
Yellowish oil; [α]D28 – 27 (c 0.1, MeOH)]; UV (MeOH) λmax (log ε) 334 (3.23), 288 (3.98), 220 
(3.94) nm; ECD (c 0.9 × 10−4 M, MeOH) λ (Δε) 244 (+0.68) nm, 269 (+0.96) nm, 295 (−2.07), 
320 (+0.18) nm (Fig. 3); HRESIMS m/z 317.1016 [M + H]+ (calcd for C17H17O6, 317.1020). 
 
2.3.2. 6-Hydroxy-8-demethoxy-4′-O-methyl-3,9-dihydropunctatin (8) 
 
Light yellow amorphous powder; [α]D28 – 36 (c 0.1, MeOH)]; UV (MeOH) λmax (log ε) 360 
(3.32), 291 (4.05), 242 (3.94), 229 (3.99) nm; ECD (c 0.9 × 10−4 M, MeOH) λ (Δε) 260 (+2.02) 
nm, 293 (−4.79), 323 (+0.50) nm (Fig. 3); HRESIMS m/z 317.1016 [M + H]+ (calcd for 
C17H17O6, 317.1020). 
 
2.3.3. 7,4′-O-dimethyl-8-demethoxy-3,3′-dihydroxy-3,9-dihydropunctatin (13) 
 
White amorphous powder; [α]D28 – 96 (c 0.05, MeOH)]; UV (MeOH) λmax (log ε) 334 (3.35), 288 
(4.08), 218 (4.10) nm; ECD (c 0.9 × 10−4 M, MeOH) λ (Δε) 253 (+1.80) nm, 295 (−3.52), 320 
(−0.53) nm (Fig. 3); HRESIMS m/z 347.1122 [M + H]+ (calcd for C18H19O7, 347.1125). 
 
2.3.4. 7-O-methyl-3-hyroxy-3,9-dihydropunctatin (14) 
 
Light yellow amorphous powder; [α]D28 – 170 (c 0.1, MeOH)]; UV (MeOH) λmax (log ε) 348 
(3.58), 292 (4.15), 224 (4.15) nm; ECD (c 0.9 × 10−4 M, MeOH) λ (Δε) 265 (+4.16) nm, 292 
(−4.53), 313 (+0.42) nm (Fig. 3); HRESIMS m/z 347.1124 [M + H]+ (calcd for C18H19O7, 
347.1125). 
 
2.4. Cytotoxicity assay 
 
Compounds (1–17) were tested for cytotoxicity against human melanoma cancer cells MDA-
MB-435 [17], human breast cancer cells MDA-MB-231, and human ovarian cancer cells 
OVCAR3 as described previously [18,19]. Briefly, the cell lines were propagated at 37 °C in 5% 
CO2 in RPMI 1640 medium, supplemented with fetal bovine serum (10%), penicillin 
(100 units/mL), and streptomycin (100 μg/mL). Cells in log phase growth were harvested by 
trypsinization followed by two washings to remove all traces of enzyme. A total of 5000 cells 
were seeded per well of a 96-well clear, flat-bottom plate (Microtest 96®, Falcon) and incubated 
overnight (37 °C in 5% CO2). Samples dissolved in DMSO were then diluted and added to the 
appropriate wells. The cells were incubated in the presence of test substance for 72 h at 37 °C 
and evaluated for viability with a commercial absorbance assay (CellTiter 96® AQueous One 
Solution Cell Proliferation Assay, Promega Corp, Madison, WI) that measured viable cells. 
IC50 values are expressed in μM relative to the solvent (DMSO) control. Taxol was used as a 
positive control. 
 
 
Fig. 1. Structures of compounds 1–17. 
 
 
3. Results and discussion 
 
Air-dried bulbs of B. flexuosa were extracted with CHCl3, and the resulting crude extract was 
reconstituted in a mixture of 5:4:1 H2O:CHCl3:MeOH. The dried organic extract was 
reconstituted in 1:1 MeOH/CH3CN and then defatted using hexanes. The resulting dried 
MeOH/CH3CN extract was fractionated using normal phase flash chromatography. HPLC 
methods, preparative and semipreprative, were used for purifications of the fractions leading to 
the isolation of seventeen homoisoflavonoids (1–17) (Fig. 1). 
 
The structures of thirteen known homoisoflavonoids analogues (1–3, 5–7, 9–12, and 15–17) 
were established by comparison of NMR (1D/2D), HRMS, and ECD data with literature values 
and were identified as: 4′,5,7-trihydroxyhomoisoflavanone (1) [6], 3′-hydroxy-3,9-
dihydroeucomin (2) [6], 3,9-dihydropunctatin (3) [20], 7-O-methyl-3,9-dihydropunctatin (5) [6], 
8-O-demethyl-7-O-methyl-3,9-dihydropunctatin (6) [6], 7,4′-di-O-methyl-3′-hydroxy-3,9-
dihydropunctatin (7) [6], 6-hydroxy-7-O-methyl-3,9-dihydropunctatin (9) [6], 7-O-methyl-3′-
hydroxypunctatin (10), 3-(4-hydroxybenzyl)-5-hydroxy-6,7,8-trimethoxychroman-4-one (11) 
[21], 7-O-methyl-8-demethoxy-3-hydroxy-3,9-dihydropunctatin (12) [6], 5-hydroxy-7,8-
dimethoxychroman-4-one (15) [6], 7-O-methylpunctatin (16) [6], and isomuscomosin (17) [6], 
(Figs. S1-S3, S5-S7, S9-S12, S15-S17, Supplementary Data). 
 
Compound 4 (0.93 mg) was isolated as a yellowish oil with a molecular formula of C17H16O6 (10 
degrees of unsaturation) as determined by HRESIMS (m/z 317.1016 [M + H]+, calcd. 317.1020), 
which was further supported by 1H, 13C, and edited HSQC NMR data (Table 1, Table 2, Fig. S4, 
Supplementary Data). Compound 4 showed characteristic NMR signals indicative of a 3-
benzylchroman-4-one homoisoflavonoid analogue with very high structural similarity to 2, both 
sharing the same molecular formula. HMBC data analysis indicated the structure of 4 to be 
different from that of 2 by the methylation position. HMBC correlations from H3–7′ (δH 3.88, s) 
to C-4′ (δC 145.5) in 2 and from H3–10 (δH 3.81, s) to C-7 (δC 168.0) in 4 enabled the assignment 
of 2 as a 4′-O-methyl analogue and 4 as a 7-O-methyl analogue. In the latter, HMBC correlations 
from H-8 (δH 5.97, d, J = 2.3) to C-4a (δC 102.7), C-6 (δC 95.1), C-7 (δC 168.0), and C-8a 
(δC 163.0); from H-6 (δH 6.06, d, J = 2.3) to C-5 (δC 164.6), C-7, C-8 (δC 94.0), and C-4a, from 5-
OH (δH 12.11, s) to C-4a, C-5, and C-6 established the substitution pattern of ring A. In addition, 
HMBC correlations from H-2′ (δH 6.75, d, J = 1.3) to C-9 (δC 32.3), C-4′ (δC 142.4), and C-6′ 
(δC121.8); from H-5′ (δH 6.81, d, J = 7.9) to C-1′ (δC 131.0) and C-3′ (δC 143.8); from H-6′ 
(δH6.66, dd, J = 7.9, 1.3) to C-9, C-2′ (δC 116.3), and C-4′ established the substitution pattern of 
ring C. Further examination of the 2D NMR data established the structure of 4 (Fig. 2) as 7-O-
methyl-8-demethoxy-3′-hydroxy-3,9-dihydropunctatin. The absolute configurations of 3-
benzylchroman-4-one-type homoisoflavonoids are assigned using electronic circular dichroism 
(ECD) spectroscopy [22], in which a negative Cotton effect in the 287–295 nm region of the 
ECD curves is indicative of a 3R configuration [22]. Compound 4 showed a negative Cotton 
effect at 295 nm (Δε = −2.07) in the ECD spectrum, supporting an R-configuration at C-3 (Fig. 
3). 
 
 
 
 
Table 1. 1H NMR data for compounds 4, 8, 13, and 14 (500 MHz in CDCl3)a. 
position 4 8 13 14 
2 4.12, dd (11.4, 7.1) 4.08, dd (11.4, 7.1) 4.06, d (11.2) 4.09, d (11.2) 
 4.28, dd (11.4, 4.1) 4.25, dd (11.4, 4.1) 4.23, d (11.2) 4.36, d (11.2) 
3 2.80, m 2.78, m   
6 6.06, d (2.3)  6.11, d (2.3) 6.16, s 
8 5.97, d (2.3) 6.05, s 6.05, d (2.3)  
9 2.65, dd (13.9, 10.4) 2.69, dd (13.8, 10.6) 2.89, d (13.8) 2.94, d (14.1) 
 3.12, dd (13.9, 4.5) 3.16, dd (13.8, 4.5) 2.93, d (13.8) 2.98, d (14.1) 
10 3.81, s  3.85, s 3.91, s 
11   3.88, s 3.83, s 
12  3.91, s   
2’ 6.75, d (1.3) 7.08, d (8.5) 6.82, d (2.1) 7.04, d (8.5) 
3’  6.78, d (8.5)  6.75, d (8.5) 
5’ 6.81, d (7.9)  6.76, d (8.1)  
6’ 6.66, dd (7.9, 1.3)  6.65, dd (8.1, 2.1)  
3-OH   3.36, s  
5-OH 12.11, s 11.78, s 11.25, s 11.21, s 
6-OH  5.03, br. s   
7-OH  4.81, br. s   
3′-OH 5.20 or 5.33b, br. s  5.58, s  
4’-OH 5.20 or 5.33b, br. s   4.83, br. s 
aδ in ppm, mult (J in Hz); bCould be swapped. 
 
Table 2. 13C NMR data for 4, 8, 14 (125 MHz), and for 13 (175 MHz) in CDCl3. 
position 4 8 13 14 
2 69.1 69.4 71.9 72.5 
3 46.9 47.2 72.3 72.2 
4 198.0 198.8 198.3 198.6 
4a 102.7 102.5 100.6 100.4 
5 164.6 148.2 164.1 160.0 
6 95.1 156.1 95.5 93.7 
7 168.0 127.4 168.8 162.3 
8 94.0 91.1 94.6 129.9 
8a 163.0 154.8 162.9 153.5 
9 32.3 32.1 41.0 40.9 
10 55.8  56.0 56.6 
11   56.0 61.7 
12  56.5   
1’ 131.0 130.1 127.3 126.2 
2’ 116.3 130.5 116.8 131.9 
3’ 143.8 115.7 145.4 115.4 
4’ 142.4 154.5 145.9 155.0 
5’ 115.7  110.5  
6’ 121.8  122.2  
 
 
Fig. 2. Key COSY and HMBC correlations of 4, 8, 13, and 14. 
 
 
 
Fig. 3. ECD spectra for compounds A) 4, B) 8, C) 13, and D) 14 [0.09 mM, MeOH, cell length 
2 cm]. 
 
HRESIMS and NMR data of compound 8 (2.3 mg), which was obtained as a yellow amorphous 
powder, revealed its molecular formula as C17H16O6 (m/z 317.1016 [M + H]+, calcd 317.1020) 
(Table 1, Table 2, Fig. S8, Supplementary Data). As in compound 4, the NMR data of 8 showed 
characteristic signals indicative of a 3-benzylchroman-4-one-type homoisoflavonoid with 
structural similarity to 3 as they shared the same molecular formula. However, the 8-methoxy 
group of ring A (δH/δC 3.95/61.7 for H3–11/C-11) in 3 was replaced by an aromatic proton 
singlet (δH/δC 6.05/91.1 for H-8/C-8) in 8. In addition, the aromatic proton singlet 
(δH/δC 6.13/96.0 for H-6/C-6) in 3 was replaced by an exchangeable proton singlet (δH 5.03 for 6-
OH) in 8. Moreover, the exchangeable proton singlet in 3 (δH 4.75 for 4′-OH) was replaced by 
a methyl group (δH/δC 3.91/56.5 for H3–7´/C-7′). The structure of 8was inferred by further 
analysis of HMBC data. HMBC correlation from H-8 to C-4 (198.8), C-4a (102.5), C-6 (156.1), 
and C-8a (154.8) established the substitution pattern of ring A, while the HMBC correlation from 
H3–7′ (δH 3.91, s) to C-4′ (δC 154.5) confirmed the methylation position in 8. Further analysis of 
the 2D NMR data established the structure of 8 to which the trivial name 6-hydroxy-8-
demethoxy-4′-O-methyl-3,9-dihydropunctatin was assigned (Fig. 2). A negative Cotton effect at 
293 nm in the ECD spectrum of compound 8(Δε = −4.79) indicated an R-configuration at C-3 
(Fig. 3). 
 
Compound 13 (0.66 mg) was obtained as a white amorphous powder. HRESIMS (m/z347.1122 
[M + H]+, calcd 347.1125) NMR data indicated a molecular formula of C18H18O7(Table 1, Table 
2, Fig. S13, Supplementary Data). The NMR data indicated compound 13as a 3-benzyl-3-
hydroxychroman-4-one homoisoflavonoid analogue. The compound showed high structural 
similarity to 12. However, compound 13 showed a methoxy group, as indicated by 1H and 13C 
NMR data (δH/δC 3.88/56.0) and a hydroxyl group at δH 5.58 (3’-OH) consistent with the 30 amu 
difference in the HRMS data of 13 relative to 12. The aromatic A2B2 system of ring B in 12 was 
replaced by an ABM spin system in 13 (δH 6.82, d, J = 2.1; 6.76, d, J = 8.1; and 6.65, dd, J = 8.1, 
2.1, for H-2´, H-5´, and H-6´, respectively), indicating the presence of a 1,3,4-trisubstituted 
benzene ring. An HMBC correlation from the 4′-OCH3 protons to C-4´ (δC 145.9) confirmed its 
connectivity. The structure of compound 13 was deduced by further inspection of the 2D NMR 
data, including COSY and HMBC spectra (Fig. 2). Compound 13 was given the trivial name 
7,4′-O-dimethyl-8-demethoxy-3,3′-dihydroxy-3,9-dihydropunctatin. A negative Cotton effect 
(Δε = −3.52) at 297 nm of the ECD spectrum of 13 indicated an S-configuration at C-3 (Fig. 3) 
[22]. 
 
The HRESIMS (m/z 347.1124 [M + H]+, calcd 347.1125) and NMR data of compound 14 
(2.38 mg), which was obtained as a light yellow amorphous powder, indicated a molecular 
formula of C18H18O7 (Table 1, Table 2, Fig. S14, Supplementary Data). The NMR data of 14 
showed distinctive peaks indicative of a 3-benzyl-3-hydroxychroman-4-one homoisoflavonoid 
analogue. The compound showed high structural similarity to 12. However, compound 14 had an 
extra methoxy group, as indicated by 1H and 13C NMR data (δH/δC 3.83/61.7), consistent with the 
30 amu difference in the HRMS data of 14 relative to 12, replacing the aromatic doublet (δH 
6.05, d, J = 2.1 for H-8) in 12. HMBC correlations from H-6 to C-4 (198.6), C-4a (100.4), C-5 
(160.0), C-7 (162.3), and C-8 (129.9) confirmed the substitution pattern of ring A. The structure 
of compound 14 was deduced by further inspection of the 2D NMR data, including COSY and 
HMBC spectra (Fig. 2). Compound 14was given the trivial name 7-O-methyl-3-hyroxy-3,9-
dihydropunctatin. A negative cotton effect (Δε = −4.53) at 292 nm in the ECD spectrum of 14 
was indicative of an S-configuration at C-3 (Fig. 3) [22]. 
 
Compounds (1–17) were evaluated for their cytotoxic activities against the MDA-MB-435 
(melanoma), MDA-MB-231 (breast), and OVCAR3 (ovarian) cancer cell lines. Compounds 2 
and 7 were the most potent on the three cancer cell lines with IC50 values of 1.6, 14.2, 9.5 and 
2.0, 3.6, and 10.8 μM, respectively (Table 3). Compound 2 was reported to be active against 
colon cancer (HT-29 cell line ED50 = 2.78 μM) and breast cancer (MDA-MB-435 cell line 
ED50 = 1.33 μM). Compounds 2 and 7 were reported previously by our group to be active against 
breast cancer (MDA-MB-435 cell line) with IC50 values of 1.0 and 1.1 μM, respectively [6]. 
Moreover, compound 7 showed moderate activity when tested against colon cancer (HT-29 cell 
line IC50 = 17.3 μM) [6]. The cytotoxicity data of the new and known analogues isolated in the 
current work expanded our understanding of the structure-activity relationships of this unique 
class of flavonoids. The substitution pattern of ring B affects the activity significantly. 
Compound 1, with a 4′-OH group, was inactive. However, compound 4, with 3′,4′-dihydroxy 
substituents, showed IC50 values of 14.3, 17.5, and 24.8 μM against the MDA-MB-435, MDA-
MB-231, and OVCAR3 cancer cell lines, respectively. Moreover, reducing the polarity of the 
ring B substituents results in improved cytotoxic activity. For example, the activity of compound 
2, with a 4′-methoxy substituent, increased by ~9- and 3-folds the activity against MDA-MB-435 
and OVCAR3 cancer cell lines in comparison with compound 4 via IC50 values of 1.6 and 9.5 
μM, respectively. Similarly, although compound 10 was inactive, compound 7, with a 4′-
methoxy substituent, showed IC50 values of 2.0, 3.6, and 10.8 μM against the MDA-MB-435, 
MDA-MB-231, and OVCAR3 cancer cell lines, respectively. The same pattern can be noticed 
when comparing the cytotoxic activities of compounds 12 and 13. Compound 12 with a 4′-OH 
substituent was inactive, however compound 13, with 3′-hydroxy and 4′-methoxy substituents, 
showed activity against the MDA-MB-435 cancer cell line with IC50 value of 14.4 μM. In 
addition, introducing an OH group at C-3 increases the activity significantly, although compound 
5 was inactive, compound 14, with a 3-OH substituent, showed IC50 value of 15.2 μM against the 
MDA-MB-435 cancer cell line. 
 
Table 3. Cytotoxic activities of compounds 2, 4, 7, 13, and 14. 
compounda IC50 values in μMb 
MDA-MB-435 Ovcar3 MDA-MB-231 
2 1.6 14.2 9.5 
4 14.3 17.5 24.8 
7 2.0 3.6 10.8 
13 14.4 >25 >25 
14 15.2 >25 >25 
Taxolc 0.0001 0.0015 0.17 
aCompounds 1, 3, 5, 6, 8–12, 15–17 were inactive, IC50 values >25 μM. bIC50 is the concentration to inhibit 50% of 
growth with a 72 h incubation. cPositive control. 
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